LLY · 10-Q · 2026Q3 · Full report

Geographic Market Commentary - China & International

ELI LILLY & Co · 2026-10-29 · Importance 63 · Surprise 64

Outside the U.S., Mounjaro revenue increased 93% in the third quarter and 153% over the first nine months of 2026, primarily from volume growth. Lower realized prices partly offset that growth, driven primarily by Mounjaro’s inclusion on China’s National Reimbursement Drug List (NRDL). The company also reports international launches of Mounjaro and submissions or launches of orforglipron in all major markets.

Key facts

• Outside-U.S. revenue for the three months ended September 30, 2026 was $9,261 million, compared with $6,301 million in 2025; nine-month outside-U.S. revenue was $25,502 million, compared with $15,283 million. source
• Outside the U.S., Mounjaro revenue increased 93% and 153% during the three and nine months ended September 30, 2026, respectively, primarily due to volume growth, partly offset by lower realized prices following its inclusion on China's NRDL. source
• Lilly has launched Mounjaro internationally and has submitted or launched orforglipron for obesity and/or type 2 diabetes in all major markets. source
• Outside the U.S., Mounjaro volume growth drove revenue increases in the three and nine months ended September 30, 2026, while lower realized prices were primarily driven by its inclusion on China's NRDL. source